

FDA approves Lupin's new generic

23 June 2016 | News | By BioSpectrum Bureau

FDA approves Lupin's new generic



Pharma Major Lupin announced that its US subsidiary, Gavis Pharmaceuticals LLC., (collectively Lupin) has received final approvals for its Voriconazole Tablets, 50 mg & 200 mg and Voriconazole Oral Suspension, 40 mg/mL from the United States Food and Drug Administration (FDA) to market a generic equivalent of PF Prism C.V's Vfend Tablets, 50 mg & 200 mg and Vfend Oral Suspension, 40 mg/mL. Lupin shall commence promoting the products in the US shortly.

Voriconazole Tablets, 50 mg & 200 mg and Voriconazole Oral Suspension, 40 mg/mL are the AB rated generic equivalent of PF Prism C.V's Vfend Tablets, 50 mg & 200 mg and Vfend Oral Suspension, 40 mg/mL. It is indicated for use in patients 12 years of age and older in the treatment of the following fungal infections:

- Invasive Aspergillosis

- Candidemia in Non-neutropenic patients and the following Candida infections: Disseminated infections in skin and infections in abdomen, kidney, bladder wall and wounds

- Esophageal Candidiasis

- Serious fungal infections caused by *Scedosporium apiospermum* (Asexual form of *Pseudallescheria boydii*) and *Fusarium* spp. including *Fusarium solani* in patients intolerant of or refractory to other therapy

Vfend Tablets, 50mg & 200mg had US sales of \$92.8 million (IMS MAT March 2016) while Vfend Oral Suspension, 40 mg/mL had US sales of USD 15.9 million (IMS MAT March 2016).